From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Study | No. patients | Median PFS (months) | HR |
---|---|---|---|
CA209-067 | n + i = 314 n = 316 | n + i = 11.5 n = 6.93 | HR 0.79 |
CA209-227 (PFS TMB High) | n + i = 101 n = 102 | 1 yr n + i = 42% n = 29% | HR 0.75 |
CA209-227 (PFS PD-L1 > 1%) | n + i = 396 n = 396 | n + i = 5.1 n = 4.2 | HR 0.83 |